Aktiesnakken — Marts 2010
-
nordea om genmab :The negative outcome and that
there are few triggers in the short term prompt us to cut our target price
to DKK 100 (fro -
DKK 100 (from DKK 140 ). We keep our Buy rating on the stock
-
ja de kommer helt op fra 140
-
ja tror det her er all time low sentiment for Genmab, men jeg bemærker lige at det IKKE er alltime low for selskabet. Arzerra er på markedet
-
hvad tænker hendricus mon
-
tør van de klinkler mon overhovedet komme tilbage til holland nu på besøg?
-
ja hrmunk, det mener jeg også
-
pliing karbold
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind